London stock exchange
Stocks and Finance

GlaxoSmithKline

GlaxoSmithKline 23/05/2012

19:01 : GSK to drop Human Genome bid if 'poison pill' stands - LONDON (Reuters) - GlaxoSmithKline said it would not proceed with its $2.6 billion offer for Human Genome Sciences unless the U.S. biotechnology company dropped a "poison pill" shareholder rights plan imposed to block the deal.
Source : reuters-com
12:47 : GlaxoSmithKline PLC GSK amends HGS tender offer conditions - TIDMGSK RNS Number : 9539D GlaxoSmithKline PLC 23 May 2012 Issued: Wednesday 23 May 2012, London UK GSK amends tender offer conditions to address Human Genome Sciences' adoption of poison pill

GlaxoSmithKline 17/05/2012

17:49 : UPDATE: Human Genome Adopts Poison Pill With 15% Trigger To Deter Glaxo - (Updates with Glaxo response in second paragraph, updates share price) DOW JONES NEWSWIRES Human Genome Sciences Inc. (HGSI) adopted a shareholder rights plan with a 15% trigger in the wake of GlaxoSmithKline PLC's (GSK, GSK.LN) ...

GlaxoSmithKline 16/05/2012

16:41 : GlaxoSmithKline Buys Back 1.2 Million Shares - LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK.LN) Wednesday said it purchased 1.2 million ordinary shares on May 16. MAIN FACTS: -Highest price paid per share was 1427.5 pence per share. -Lowest price paid per share was 1418 ...

GlaxoSmithKline 10/05/2012

21:32 : GlaxoSmithKline 'avoided corporation tax bill of £34m', according to BBC - The UK firm set up a company in Luxembourg in 2009 and in 2010 the subsidiary lent the parent £6.34bn. The UK firm paid nearly £124m in interest to the unit in Luxembourg, so it did not have to pay corporation tax.
19:00 : GSK starts $2.6 billion tender offer for Human Genome - LONDON (Reuters) - GlaxoSmithKline launched its promised $2.6 billion (1.6 billion pounds) tender for shares in long-time partner Human Genome Sciences on Thursday, setting out an initial timetable of just under a month to win ...
Source : reuters-com

GlaxoSmithKline 09/05/2012

22:27 : GlaxoSmithKline to turn hostile over move for HGS - GSK is going hostile in its £1.6billion bid for Human Genome Sciences after its American joint venture partner last month rebuffed the offer as undervaluing the company.
18:34 : GlaxoSmithKline turns up the heat on Human Genome Sciences - it would be understandable if HGS shareholders feel GSK, after 20 years of collaboration with HGS, is forcing the pace for a reasonIt's like the old days for Simon Dingemans, the former Goldman Sachs deal-maker who quit a couple of ...
Source : guardian-co-uk
17:04 : GlaxoSmithKline Buys Back 1.5 Million Shares To Hold In Treasury - LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK.LN) announced Wednesday that on May 9 it bought 1.5 million of its own shares to hold in treasury. MAIN FACTS: -Highest price paid per share 1418.5 pence; lowest 1396 pence -Shares ...
07:49 : GSK to launch $2.6 billion Human Genome tender offer - LONDON (Reuters) - GlaxoSmithKline is to take its unsolicited $2.6 billion (1.6 billion pounds) takeover bid for Human Genome Sciences direct to shareholders in the U.S. biotech group by launching a tender offer at $13 a share this ...
Source : reuters-com

GlaxoSmithKline 03/05/2012

22:15 : ALEX BRUMMER: Aviva embarrassed as investors punish their own - It is enormously embarrassing for the company to find itself in the rogue's gallery alongside the Royal Bank of Scotland, Shell and GlaxoSmithKline, all of which have suffered similar humiliations over ...
11:43 : Germany joins UK in spurning GSK's new lupus drug - LONDON (Reuters) - Benlysta, a new drug for lupus from GlaxoSmithKline and Human Genome Sciences, has been rejected by Germany's healthcare cost watchdog in a decision that adds to the product's uphill battle in Europe.
Source : reuters-com

GlaxoSmithKline 01/05/2012

17:18 : GlaxoSmithKline Buys 305,000 Shares For Treasury - LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK.LN) said Tuesday that it bought to be held in treasury 305,000 shares at a highest price of 1444.5 pence and a lowest price of 1430.5 pence. -Shares closed Tuesday at 1,438 pence valuing ...
07:16 : Questor share tip: GlaxoSmithKline remains the pharma to own - Last week's first-quarter results from pharmaceuticals group GlaxoSmithKline were below market expectations. However, there are no changes to full-year guidance.
Source : telegraph-co-uk

GlaxoSmithKline 29/04/2012

20:46 : Shareholder: GlaxoSmithKline offer is bitter pill - GlaxoSmithKline's attempt to land its biggest acquisition since 2009 has suffered a blow after a top shareholder in Human Genome Sciences said the British group's offer was "a steal".
Source : telegraph-co-uk
14:19 : Human Genome Holder Says Glaxo Bid "Unacceptable" - Newspaper - LONDON -(Dow Jones)- A fund with a 5.6% stake in Human Genome Sciences Inc. (HGSI), the U.S. drug company for which GlaxoSmithKline PLC (GSK.LN) has made an unsolicited $2.6 billion offer, said the approach is "unacceptable", according ...

GlaxoSmithKline 27/04/2012

00:32 : FDA Approves GSK Cancer Drug Votrient For Soft-Tissue Sarcoma - WASHINGTON -(Dow Jones)- The Food and Drug Administration on Thursday approved GlaxoSmithKline PLC's (GSK, GSK.LN) cancer drug Votrient for use in patients with soft-tissue sarcoma, making it the first new treatment for the rare ...

GlaxoSmithKline 26/04/2012

23:27 : Drug company attacks Nice for rejecting new lupus treatment - GlaxoSmithKline crticises NHS pharmaceutical approval body over rejecting belimumab drugBritain's largest drug company has launched a forthright attack on the NHS's drug rationing body, accusing it of blocking innovation after it ...
Source : guardian-co-uk

GlaxoSmithKline 25/04/2012

17:49 : FTSE rises as investors eye FOMC, shrugs off GDP data - The blue-chip index closed up on Wednesday, shrugging off weak UK GDP figures showing Britain slipped back into recession and disappointing first-quarter results from drugmaker Glaxosmithkline , as investors awaited ...
Source : ibtimes-co-uk
14:36 : Price cuts weigh on Glaxo revenue - GlaxoSmithKline grew revenue just 1 per cent in the first quarter, reflecting pressures on its business from government price cuts in Europe and some emerging markets and tough year-ago comparisons.
Source : irishtimes-com
11:46 : Drugmaker GSK struggles to grow in first quarter - LONDON (Reuters) - Drugmaker GlaxoSmithKline grew revenue just 1 percent in the first quarter, reflecting pressures on its business from government price cuts in Europe and some emerging markets and tough year-ago comparisons.
Source : reuters-com

GlaxoSmithKline 24/04/2012

22:31 : Human Genome exploring options after rebuff of Glaxo - (Reuters) - Human Genome Sciences Inc , which rebuffed an unsolicited $2.6 billion (1.6 billion pounds) takeover bid by British drugmaker GlaxoSmithKline , said on Tuesday it was reviewing strategic alternatives, including the sale ...
Source : reuters-com

GlaxoSmithKline 23/04/2012

08:11 : Bombay Stock Exchange Replaces DLF With Dr Reddy's Labs In 30-Share ... - MUMBAI -(Dow Jones)- The Bombay Stock Exchange has replaced real-estate developer DLF Ltd. (532868.BY) with Dr. Reddy's Laboratories Ltd. (500124.BY) in its 30-share benchmark Sensitive Index. The exchange also replaced Glaxosmithkline ...

GlaxoSmithKline 22/04/2012

21:19 : Without state spending there'd be no Google or GlaxoSmithKline | Mariana ... - Forget the fearful private sector. Entrepreneurs depend on public funds to make the early, risky investmentsIn today's low-growth Britain, politicians and newspapers regularly celebrate individual business leaders. GlaxoSmithKline's Andrew Witty and ...
Source : guardian-co-uk

GlaxoSmithKline 20/04/2012

17:02 : GlaxoSmithKline sells clutch of drugs for £164m to Aspen - GlaxoSmithKline has offloaded a clutch of its over-the-counter drugs in a £164m deal, but has still been unable to sell its weight loss treatment, Alli.
Source : telegraph-co-uk

GlaxoSmithKline 19/04/2012

13:27 : Human Genome Sciences rejects $2.6bn bid from GlaxoSmithKline - GlaxoSmithKline's long-term partner Human Genome Sciences said offer of $13 a share did not reflect firms' inherent valueGlaxoSmithKline has swooped on its long-term partner Human Genome Sciences with a $2.6bn (£1.6bn) hostile offer, which was immediately ...
Source : guardian-co-uk
11:24 : GSK pounces on Human Genome with $2.6 billion bid - LONDON (Reuters) - Human Genome Sciences Inc said on Thursday it had rejected an unsolicited bid worth around $2.6 billion from long-time partner GlaxoSmithKline Plc, marking a new takeover battle in a drugs sector that has been ...
Source : reuters-com
10:53 : GlaxoSmithKline sees $2.6bn bid for US partner Human Genome rejected - US group already partners Glaxo but says its offer undervalues the businessGlaxoSmithKline has made a $2.6bn bid for US partner Human Genome Sciences, which has been immediately rejected.The drugs sector has seen a wave of mergers and acquisitions, and ...
Source : guardian-co-uk

GlaxoSmithKline 06/04/2012

21:07 : GlaxoSmithKline puts £3m into Rwandan rural clinics - Britain's biggest drug maker, GlaxoSmithKline, has backed Rwanda's drive to expand its health care services by investing almost £3m in a series of rural clinics.
Source : telegraph-co-uk

GlaxoSmithKline 02/04/2012

13:42 : GSK ups lung drug bet by buying more of Theravance - LONDON (Reuters) - GlaxoSmithKline bet another $212.9 million (133 million pounds) on the success of lung drug Relovair on Monday by raising its stake in U.S. biotech firm Theravance - its partner on the new medicine - to 26.8 percent.
Source : reuters-com
actualidad GlaxoSmithKline -

Copyright © 2009 Finaperf.com - Bourse - Börse - Day trading - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts